Barbiturates and meprobamate: decreases in cathecholamine turnover of central dopamine and noradrenaline neuronal systems and the influence of immobilization stress.
D000818:Animals; D001463:Barbiturates / Q000494:pharmacology*; D001921:Brain / Q000201:enzymology / Q000378:metabolism*; D002525:Cerebellar Cortex / Q000187:drug effects / Q000378:metabolism; D002540:Cerebral Cortex / Q000187:drug effects / Q000378:metabolism; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism; D004298:Dopamine / Q000378:metabolism*; D005453:Fluorescence; D007031:Hypothalamus / Q000187:drug effects / Q000378:metabolism; D007103:Immobilization; D008032:Limbic System / Q000187:drug effects / Q000378:metabolism; D008297:Male; D008620:Meprobamate / Q000494:pharmacology*; D008781:Methyltyrosines / Q000494:pharmacology; D008995:Monoamine Oxidase / Q000378:metabolism; D009638:Norepinephrine / Q000378:metabolism*; D051381:Rats; D013312:Stress, Physiological / Q000378:metabolism*; D013378:Substantia Nigra / Q000187:drug effects / Q000378:metabolism; D014446:Tyrosine 3-Monooxygenase / Q000037:antagonists & inhibitors
D001463:Barbiturates; D008781:Methyltyrosines; D008620:Meprobamate; D014446:Tyrosine 3-Monooxygenase; D008995:Monoamine Oxidase; D004298:Dopamine; D009638:Norepinephrine